期刊文献+

乳腺癌不同分子亚型腋窝淋巴结转移的状态及预后分析 被引量:7

Axillary Lymph Nodes Metastasis of Various Breast Cancer Molecular Subtypes and Its Prognostic Analysis
原文传递
导出
摘要 目的探讨乳腺癌不同分子亚型腋窝淋巴结转移的状态及预后分析。方法对2005年1月2007年12月收治的125例乳腺癌患者进行分子分型,对腋窝淋巴结转移状态进行分析并结合随访结果进行预后分析。结果 Luminal A型63例,16例淋巴结转移,转移率为25.4%;Luminal B型19例,7例淋巴结转移,转移率为36.8%;HER-2过表达型26例,11例淋巴结转移,转移率为42.3%;Basal-like型17例,9例淋巴结转移,转移率为52.9%。其中Luminal A型淋巴结转移率与Basal-like型比较差异有统计学意义(P<0.05),其余型间比较差异无统计学意义(P>0.05)。运用χ2检验各分子亚型在肿瘤大小的差异无统计学意义(P>0.05)。经过2~5年随访,8例患者出现局部复发或远处转移,其中Luminal B型2例,HER-2过表达型5例,Basal-like型1例。8例中有3例因肝转移死亡,另5例接受治疗现仍生存。结论乳腺癌的分子分型可作为腋窝淋巴结转移的预测指标,HER-2过表达型和Basal-like型预后较差,将为今后制定乳腺癌个体化治疗提供重要依据。 Objective To analyze the axillary lymph nodes metastasis of various breast cancer molecular subtypes and its prognosis.Methods Molecular subtypes of 125 cases of operable breast cancer diagnosed and treated between January 2005 and December 2007 were categorized,and the axillary lymph nodes metastasis of these types was analyzed.At the same time,we analyzed its prognosis status with the results of the follow-up.Results Among the 125 cases,there were 63 luminal A cases in which 16(25.4%) were found to be axillary lymph nodes metastasis.Among the 19 luminal B cases,there were 7(36.8%) axillary lymph nodes metastases.There were 11 cases(42.3%) of axillary lymph nodes metastasis in the 26 cases of HER-2(+) subtype.In the 17 cases of basal-like subtye,9(52.9%) were axillary lymph nodes metastases.As for the axillary lymph nodes metastatic rate,only basal-like subtype was higher than luminal A subtype with a statistically significant difference(P0.05).Differences between all other subtypes were not significant(P0.05).The molecular subtypes did not differ in tumor size(P0.05) according to the result of chi-square test.During the 2 to 5-year follow-up,8 of the 125 patients were found to have local tumor recurrence or distant metastatic disease,which included 2 luminal B cases,5 HER-2(+) subtype cases,and 1 basal-like subtype case.In those 8 patients,3 died of liver metastases and 5 survived and are still accepting treatment now.Conclusion Molecular subtyping can provide important information of axillary lymph nodes metastatic status.HER-2 over-expression and basal-like subtype have a poor prognosis,which is an important basis for individual treatment of breast cancer in the future.
出处 《华西医学》 CAS 2011年第7期971-974,共4页 West China Medical Journal
基金 湖北省妇幼保健院资助课题(20917014)~~
关键词 乳腺肿瘤 分子亚型 淋巴结转移 预后 Breast cancer Molecular subtype Lymph node metastasis Prognosis
  • 相关文献

参考文献15

  • 1Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-2502.
  • 2Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J]. Nature, 2000, 406(6797): 747-752.
  • 3Ihemelandu CU, Naab JT, Mezghebe HM, et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women[J]. Am J Surg, 2008, 195(2): 153-158.
  • 4Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8): 2329-2334.
  • 5Liu H, Fan Q, Zhang Z, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor- negative invasive breast eaneers[J]. Hum Pathol, 2008, 39(2): 167-174.
  • 6Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival [J]. Clin Cancer Res, 2007, 13(15 Pt 1).. 4415-4421.
  • 7Millikan RC, Newman B, Tse CK, etal. Epidemiology of basal- like breast cancer[J]. Breast Cancer Res Treat, 2008, 109(1):123-139.
  • 8Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
  • 9Ihemelandu CU, Naab JT, Mezghebe HM, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival [J]. J Surg Res, 2007, 143(1): 109-118.
  • 10Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities [J]. Eur J Cancer, 2004, 40(18) : 2667-2675.

二级参考文献19

  • 1Perou CM,Sφrlie T,Eisen MB,et al.Molecular portraits of human breast tumours.Nature,2000,406:747-752.
  • 2Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci U S A,2003,100:8418-8423.
  • 3Liu H,Fan Q,Zhang Z,et al.Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.Hum Pathol,2008,39:167-174.
  • 4Yamamoto Y,Ibusuki M,Kawasoe T.Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer.J Clin Oncol,2008,26(Suppl):abstr 22184.
  • 5Wiechmann L,Sampson M,Stempel M,et al.Presenting features of breast cancer differ by molecular subtype.Ann Surg Oncol,2009,16:2705-2710.
  • 6Parise CA,Bauer KR,Brown MM,et al.Breast cancer subtypes as defined by the estrogen receptor (ER),progesterone receptor (PR),and the human epidermal growth factor receptor 2(HER2) among women with invasive breast cancer in California,1999-2004.Breast J,2009,15:593-602.
  • 7Hugh J,Hanson J,Cheang MC,et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial.J Clin Oncol,2009,27:1168-1176.
  • 8Goldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for therapies:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009,Ann Oncol,2009,20:1319-1329.
  • 9Ellis MJ,Coop A,Singh B,et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive,estrogen receptor-positive primary breast cancer:evidence from a phase Ⅲ randomized trial.J Clin Oncol,2001,19:3808-3816.
  • 10O'Shaughnessy J,Osborne C,Pippen J,et al.Efficacy of BSI201,a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor,in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC):Results of a randomized phase Ⅱ trial.J Clin Oncol,2009,27(Suppl):abstr3.

共引文献14

同被引文献60

  • 1陈蓉,龚水根,张伟国,陈金华,何双梧,刘宝华,李增鹏.乳腺癌MRI形态学表现与病理、分子生物学相关性研究[J].中华放射学杂志,2004,38(6):620-625. 被引量:55
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:163
  • 3洪玉蓉,刘学明,张闻,莫国强,许俊,魏红权.超声造影在浅表淋巴结疾病鉴别诊断中的应用研究[J].中华超声影像学杂志,2006,15(11):849-852. 被引量:77
  • 4Dunnwald LK, Rossing MA, Li Cl. Hormone receptor status,tumor characteristics, and prognosis: A prospective cohort ofbreast cancer patients. Breast Cancer Res, 2007,9(1) :R6.
  • 5Goldberg BB, Merton.DA, Liu JB, et al. Sentinel lymph nodes ina swine model with melanoma : Contrast-enhanced lymphatic US.Radiology, 2004,230(3):727-734.
  • 6Lurie DM, Seguin B, Schneider PD, et al. Contrast-assisted ul-trasound for sentinel lymph node detection in spontaneously ari-sing canine head and neck tumors. Invest Radiol, 2006,41 (4):415-421.
  • 7Perou CT, Eisen MB. Molecular portaits of human breasttumors. Nature, 2000,406(6797) :747-752.
  • 8Van Calster B, Vanden Bempt I, Drijkoningen M, et al. Axillarylymph node status of operable breast cancers by combined steroidreceptor and HER-2 status: Triple positive tumours are morelikely lymph node positive. Breast Cancer Res Treat, 2009,113(1):181-187.
  • 9Huang HJ, Neven P, Drijkoningen M, et al. Association be-tween tumour characteristics and HER-2/neu by immunohisto-chemistry in 1362 women with primary operable breast cancer. JClin Pathol, 2005,58(6〉: 611-616.
  • 10Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressedgene related to p53 at lp36,a region frequently deleted in neu-roblastoma and other human cancers. Cell, 1997, 90(4):809-819.

引证文献7

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部